Retatrutide: What the Research Shows
Also known as: LY3437943, Triple Agonist
A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.
This content is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before making any health decisions. Full disclaimer
Quick Facts
Regulatory Status
Currently in Phase 3 clinical trials. Not yet FDA-approved. Triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly.
Researched Applications
Key Research (1 studies cited)
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes
human rctRosenstock J, et al. (2023) — New England Journal of Medicine — n=338
Phase 2 trial showing retatrutide produced up to 24.2% body weight loss at 48 weeks, surpassing tirzepatide results.
Key finding: Retatrutide 12mg produced mean weight loss of 24.2% at 48 weeks, the highest reported for any anti-obesity medication in trials.
PubMed: 37351564About this article: Written by the PeptideMark Research Team. Last reviewed 2026-03-11. All factual claims are cited to peer-reviewed sources. PubMed links open in a new tab for independent verification. Editorial methodology · Medical disclaimer
The Peptide Brief
Weekly peptide research digest. No spam.